Dr. Natarajan Sethuraman, previously Chief Scientific Officer, has been promoted to President of Research and Development at Entrada Therapeutics, effective September 24, 2024. Dr. Sethuraman has been with Entrada since its inception in 2017 and has been instrumental in the research and clinical development of the company's diverse pipeline.
His leadership has helped advance the ENTR-601-44 program into the clinic and establish a dedicated team. Dr. Sethuraman brings deep and broad experience in end-to-end therapeutics development across multiple modalities, including oligonucleotides, antibodies, therapeutic enzymes, and peptides.
This executive promotion underscores Entrada's commitment to leveraging its internal talent and expertise to drive its innovative Endosomal Escape Vehicle (EEV) platform and expand its portfolio of proprietary intracellular therapeutics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.